Causal Analysis of the TOPCAT Trial: Spironolactone for Preserved Cardiac Function Heart Failure
Abstract
We describe the results of applying causal discovery methods on the data from a multi-site clinical trial, on the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT). The trial was inconclusive, with no clear benefits consistently shown for the whole cohort. However, there were questions regarding the reliability of the diagnosis and treatment protocol for a geographic subgroup of the cohort. With the inclusion of medical context in the form of domain knowledge, causal discovery is used to demonstrate regional discrepancies and to frame the regional transportability of the results. Furthermore, we show that, globally and especially for some subgroups, the treatment has significant causal effects, thus offering a more refined view of the trial results.
Cite
Text
Raimondi et al. "Causal Analysis of the TOPCAT Trial: Spironolactone for Preserved Cardiac Function Heart Failure." NeurIPS 2022 Workshops: CML4Impact, 2022.Markdown
[Raimondi et al. "Causal Analysis of the TOPCAT Trial: Spironolactone for Preserved Cardiac Function Heart Failure." NeurIPS 2022 Workshops: CML4Impact, 2022.](https://mlanthology.org/neuripsw/2022/raimondi2022neuripsw-causal/)BibTeX
@inproceedings{raimondi2022neuripsw-causal,
title = {{Causal Analysis of the TOPCAT Trial: Spironolactone for Preserved Cardiac Function Heart Failure}},
author = {Raimondi, Francesca and O'Keeffe, Tadhg and Chockler, Hana and Lawrence, Andrew and Stemberga, Tamara and Franca, Andre and Sipos, Maksim and Butler, Javed and Ben-Haim, Shlomo},
booktitle = {NeurIPS 2022 Workshops: CML4Impact},
year = {2022},
url = {https://mlanthology.org/neuripsw/2022/raimondi2022neuripsw-causal/}
}